One shot, three viruses? new vaccine trial targets RSV, hMPV, and PIV3 in seniors
NCT ID NCT06604767
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 1 study tests a new vaccine that aims to protect against three respiratory viruses at once: RSV, hMPV, and PIV3. The trial involves 390 adults aged 60 and older and will check if the vaccine is safe and helps the body produce antibodies. Different combinations and doses are being compared to find the best approach.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Combined vaccine targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and parainfluenza virus type 3 (PIV3)
What this could lead to
If successful, this could lead to a single vaccine that protects older adults from three common respiratory viruses, potentially reducing severe illness and hospitalizations.
What could go wrong
This is an early Phase 1 trial with only 390 participants, so safety and immune response are still being tested. It may not work as hoped, and side effects like injection site reactions or fever are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number : 0360001
Botany, New South Wales, 2019, Australia
-
Investigational Site Number : 0360002
Camberwell, Victoria, 3124, Australia
-
Investigational Site Number : 0360003
Bayswater, Victoria, 3153, Australia
-
Investigational Site Number : 0360004
Miranda, New South Wales, 2228, Australia
-
Investigational Site Number : 0360005
Kanwal, New South Wales, 2259, Australia
-
Investigational Site Number : 0360006
Blacktown, New South Wales, 2148, Australia
-
Investigational Site Number : 0360008
Herston, Queensland, 4006, Australia
-
Investigational Site Number : 0360009
Brookvale, New South Wales, 2100, Australia